C12Y 118/01006
Adrenodoxin-nadp+ reductase
Official title: Adrenodoxin-NADP+ reductase (1.18.1.6)
C12Y118/01006 (Adrenodoxin-nadp+ reductase) appears on 4 US grants and 5 published applications in this corpus.
Search patents in C12Y- Granted patents
- 4
- Published applications
- 5
- Assignees
- 4
- Inventors
- 21
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 0 |
| 2024 | 1 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Targeted expression of microbial cholesterol catalysis genes reduces excess lipid10 Feb 2026US 12,544,402 B2Repair Biotechnologies, Inc.
- 21-hydroxylation of steroids23 Apr 2024US 11,965,199 B2Sanofi
- 21-hydroxylation of steroids21 Mar 2023US 11,608,514 B2Euroapi
- 21-hydroxylation of steroids20 Aug 2019US 10,385,376 B2Sanofi
- 21-Hydroxylation of Steroids21 Jul 2022US 2022/0228189 A1Sanofi
- Targeted expression of microbial cholesterol catalysis genes reduces excess lipid2 Sep 2021US 2021/0268019 A1Repair Biotechnologies, Inc.
- 21-Hydroxylation of Steroids21 Nov 2019US 2019/0352690 A1Euroapi
- Electron transport chain module from eukaryotic organelle and application thereof7 Nov 2019US 2019/0338257 A1Peking University
- 21-Hydroxylation of Steroids9 Nov 2017US 2017/0321241 A1Sanofi
Most cited
By later US patents